{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031188","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.880694+00:00","generated_at":"2026-06-08T06:00:23.905527+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Integrated BioPharma Q1 revenue up 4.9% to $12.9M; net loss widens to $59K","bullets":["Revenue $12.9M vs $12.3M YoY, a 4.9% increase.","Operating loss of $54K vs operating income of $30K in prior year.","Net loss of $59K ($0.00 per share) vs net loss of $35K ($0.00 per share).","Two largest customers represent 91% of Q1 revenue in Contract Manufacturing Segment.","Co-CEOs cite revenue growth from top customers."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031188","json":"https://secwatch.observer/filing/0001437749-23-031188.json","markdown":"https://secwatch.observer/filing/0001437749-23-031188.md","text":"https://secwatch.observer/filing/0001437749-23-031188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774923031188/0001437749-23-031188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774923031188/inbp20231107_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:00:23.905527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ccc4837910383439a7c7aa9c25d90afe7fc7337","claim":"INTEGRATED BIOPHARMA INC reported the quarter ended September 30, 2023 results: revenue $12.9 million, net income net loss of approximately $59,000 or $0.00 per share, EPS $0.00 per share of common stock.","evidence_excerpt":"Inc. (OTCQX: INBP) (the “Company” or “INBP”) reports its financial results for the quarter ended September 30, 2023. Revenue for the quarter ended September 30, 2023 was $12.9 million compared to $12.3 million for the quarter ended September 30, 2022, an increase of $0.6 million or approximately 4.9%. The Company had an operating loss for the quarter ended","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774923031188/0001437749-23-031188-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$12.9 million"},{"label":"Net income","value":"net loss of approximately $59,000 or $0.00 per share"},{"label":"EPS","value":"$0.00 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}